peekaboo™
Early Detection Gender DNA Test

Clinical-Study Results and Competitor Comparison

Peekaboo™: A Highly-Accurate Molecular Test for Fetal Gender as Early as 7 Weeks of Gestation

A clinical study of 215 pregnant women ranging between 7 and 39 weeks of gestation (median=9 weeks) was completed to determine the utility of the **Peekaboo Early Gender Detection Test**. Blood drawn from venipuncture was processed and gender was determined using both the qPCR-based Peekaboo test and highly-accurate (>99%) next-generation sequencing (NGS) as a gold standard. Of the 213 women in which the fetal gender could be determined, 212 of the results were concordant with NGS for an overall accuracy of 99.5%. The study contained a similar number of male and female fetuses and 27 fetuses at 7 weeks of gestation, a time when other molecular tests and ultrasound are unable to identify the gender.

Number of Samples	215
Sensitivity (Male Detection)	109/110 (99.1%)
Specificity (Female Detection)	103/103 (100%)
Accuracy	212/213 (99.5%)
Accuracy at 7 weeks	27/27 (100%)
Re-draws required	2/215 (0.9%)

Peekaboo has the advantage of minimizing processing steps following the blood draw: only inversion of the tube is required by the test administrator. The qPCR process itself is optimized to minimize contamination from sources outside the mother and fetus and indeterminate results are rare (0.9%).

Attribute	Peekaboo	Competitor
Accuracy	99.5%	99.1%
Earliest gestational age	7 weeks	8 weeks
Validation comparator	Next-Gen Sequencing	Ultrasound
Ease of use	Just draw blood; less prone to contamination	Insert solution after draw; contamination prone

The study demonstrated that the Peekaboo test is more accurate, easier to perform, and can be administered at earlier times in pregnancy than other tests on the market.

Peekaboo is a Product of DNA Diagnostics Center (DDC)

Founded in 1995, DDC is one of the largest private DNA-testing companies, offering diagnostic and genetic tests to help answer relationship, fertility, and health and wellness questions. DDC provides products cleared by the FDA and EMA, and is accredited by the American Association of Blood Banks (AABB), the Ministry of Justice, New York State Department of Health (NYSDOH), The College of American Pathologists (CAP), and the Clinical Laboratory Improvement Amendment (CLIA). DDC is also accredited by the globally-accepted ANSI National Accreditation Board (ANAB), Standards Council of Canada (SCC), and the National Association of Testing Authorities, Australia (NATA), to meet the international quality standards of ISO 17025.

DDC®
DNA Diagnostics Center